, Singapore

Lonza debuts on SGX

The pharmaceutical supplier is the first SIX Swiss-listed company to dual list in Singapore.

Lonza Group Ltd, a supplier to the pharmaceutical, healthcare and life science industries, expects to make its trading debut on the Main Board of the Singapore Exchange Securities Trading Limited at 9:00 am tomorrow, 21 October 2011 (Singapore time).

Listed on the SIX Swiss Exchange since November 1999, Lonza is the first SIX Swiss-listed company to be secondary listed by way of an introduction on the SGX-ST. Based on the closing market price of the company’s shares quoted on the SIX on 19 October 2011, Lonza has a market capitalization of approximately CHF 2,982 million. This corresponds to approximately SGD 4,183 million based on an exchange rate of CHF 1.00 to SGD 1.4028 as quoted by Bloomberg on 19 October 2011.

UBS AG, Singapore Branch acted as the issue manager for the introduction and Drew and Napier LLC acted as the solicitors to the introduction and legal advisers to the company as to Singapore law.

Lonza will be secondary listed on the SGX-ST and will not be subject to the SGX-ST’s continuing listing requirements. Lonza is subject to the listing rules of the SIX, which do not have specific requirements equivalent to the listing rules of the SGX-ST in respect of interested person transactions, acquisition and realisations, and delisting.


 

Join Singapore Business Review community
Join Singapore Business Review community
A NOTE FROM SINGAPORE BUSINESS REVIEW

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.